Business Combinations - Additional Information (Details) $ in Thousands			9 Months Ended
	Oct. 31, 2019 USD ($)	Jun. 30, 2018 USD ($) Installment shares	Sep. 30, 2020 USD ($)
Oncimmune Limited
Business Acquisition [Line Items]
Total consideration amount	$ 1,206		$ 1,200
Business acquisition description			quarterly installments commencing 30 days following the closing of the transaction.
Cash	1,206
Integrated Diagnostics, Inc
Business Acquisition [Line Items]
Total consideration amount		$ 27,587
Business acquisition description			requires additional consideration to be paid by the Company to Indi based on the Milestone of the attainment of a three consecutive month
Cash		$ 8,000
Preferred stock issued | shares		10,694,904
Contingent consideration fair value		$ 19,600
Shares issued | shares		10,649,904
Shares deposited in an escrow account | shares		2,129,981
Business acquisition contingent consideration gross margin target		$ 2,000
Business acquisition contingent consideration gross margin target period		7 years
Contingent consideration number of installments | Installment		8
Undiscounted contingent consideration payment		$ 37,000
Fair value of contingent consideration recognized		$ 19,600
Acquired technology discount rate		37.50%
Integrated Diagnostics, Inc | Series G Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition description			.  If Indi elects not to exercise these options, the Company has 12 months to settle the contingent consideration
Preferred stock issued | shares		10,649,604
Contingent consideration number of installments | Installment		2
Contingent consideration shares | shares		14,959,114
License Rights | Oncimmune Limited | United States
Business Acquisition [Line Items]
Payments to acquire license rights	$ 9,000